Sinil Pharmaceutical Co. Ltd (012790.KQ) stock: key figures, P/E, revenue and dividend

Energy · Coal & Consumable Fuels · South Korea · ISIN KR7012790002

Price
6,130.00 KRW
Market cap
70.86 bn KRW
P/E (2025)
9.41
P/S (2025)
0.88
Dividend yield
3.10 %
Net margin
9.35 %
Return on equity (ROE)
4.94 %
Return on assets (ROA)
4.44 %

Sinil Pharmaceutical Co. Ltd financials

Fiscal year20242025
Revenue89.44 bn KRW80.56 bn KRW
Gross profit40.67 bn KRW33.44 bn KRW
Operating income15.25 bn KRW7.39 bn KRW
EBIT16.56 bn KRW8.62 bn KRW
Net income14.30 bn KRW7.53 bn KRW
Diluted EPS – continuing operations1,237.13 KRW651.49 KRW

Full history since 2014, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Sinil Pharmaceutical Co. Ltd

Sinil Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers pharmaceutical products for various indications, such as pain reliever, anti-inflammatory, hyperlipidemia, skin disease, and folic acid deficiency; and general/specialty drugs, veterinary drugs, and OEM products for various diseases. The company also provides cosmetics, including skin care products, etc.; health functional products comprising vitamin supplements; and quasi-drugs for yellow dust, bacteria blocking, etc. In addition, it is involved in the real estate rental services. The company was founded in 1971 and is headquartered in Chungju-si, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.